IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

Abstract

Purpose: Ovarian clear cell adenocarcinoma (OCCA) is an uncommon histotype that is generally refractory to platinum-based chemotherapy. We analyze here the most comprehensive gene expression and copy number data sets, to date, to identify potential therapeutic targets of OCCA.Experimental Design: Gene expression and DNA copy number were carried out using primary human OCCA tumor samples, and findings were confirmed by immunohistochemistry on tissue microarrays. Circulating interleukin (IL) 6 levels were measured in serum from patients with OCCA or high-grade serous cancers and related to progression-free and overall survival. Two patients were treated with sunitinib, and their therapeutic responses were measured clinically and by positron emission tomography.Results: We find specific overexpression of the IL6-STAT3-HIF (interleukin 6-signal transducer and activator of transcription 3-hypoxia induced factor) pathway in OCCA tumors compared with high-grade serous cancers. Expression of PTHLH and high levels of circulating IL6 in OCCA patients may explain the frequent occurrence of hypercalcemia of malignancy and thromboembolic events in OCCA. We describe amplification of several receptor tyrosine kinases, most notably MET, suggesting other potential therapeutic targets. We report sustained clinical and functional imaging responses in two OCCA patients with chemotherapy-resistant disease who were treated with sunitinib, thus showing significant parallels with renal clear cell cancer.Conclusions: Our findings highlight important therapeutic targets in OCCA, suggest that more extensive clinical trials with sunitinib in OCCA are warranted, and provide significant impetus to the growing realization that OCCA is molecularly and clinically distinct to other forms of ovarian cancer. Clin Cancer Res; 17(8); 2538-48. Ó2011 AACR.

Cucurbitacin I Induces Protective Autophagy in Glioblastoma in Vitro and in Vivo

“…Further investigation documented that cucurbitacin I treatment inhibited the JAK2/STAT3 pathway, accompanied by decreased levels of HIF-1␣, which echoed the findings that the JAK2/STAT3 pathway positive regulates HIF-1␣ in a variety of cancer cell types (37)(38)(39)(40). HIF-1␣ plays an important role in hypoxia-induced autophagy, requiring specific activation of an autophagy-inducing molecule, BNIP3, which is activated by HIF-1 only in hypoxic cells (53).…”

The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer

“…However, a recent study performed by Panici and colleagues suggest that the survival between the two groups to be far closer (72 months vs 62 for types I and II respectively [6]), indicating that there is still much we don't understand about this disease. Adding to this argument, is the finding that clear cell ovarian cancer (CCOC) is genetically separate to other forms of ovarian cancer, with different common mutations [7], and de novo chemo-resistance.…”

“…Ongoing molecular characterisation and genetic studies suggests that this model may be overly simplistic, with a number of subtypes being re-classified, or further divided into additional sub-groups [8,9,7,10]. These new subtypes demonstrate different genetic lesions and transcriptional profiles, chemo-sensitivity, and survival rates, indicating a need to incorporate this information into treatment plans for ovarian cancer.…”

Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification

“…Many of the earlier classification studies in ovarian cancer focused on defining gene signatures of known traditional histologic ovarian cancer subtypes including the rare histologic types such as clear cell, mucinous or endometrioid ovarian cancer. These analyses show that clear cell and mucinous ovarian cancers can be readily distinguished from serous ovarian cancers based on their gene expression profiles, regardless of tumor stage and grade [33][34][35][36]. One of these studies also confirms that low-grade endometrioid cancers are distinctly separated from the other groups of ovarian tumors [37].…”